Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3578046 | 0.89 | ALDH1A1 (0.44) | CACNA1B | |
| SCHEMBL6016455 | 0.77 | HDAC6 (0.43) | FDPSFGFR1FGFR4HDAC6 | |
| SCHEMBL6016459 | 0.77 | HDAC6 (0.43) | FDPSFGFR1FGFR4HDAC6 | |
| SCHEMBL10314815 | 0.75 | ADORA2A (0.47) | CACNA1B | |
| SCHEMBL3582279 | 0.75 | ADORA2A (0.47) | CACNA1B | |
| SCHEMBL3577414 | 0.75 | CACNA1B (0.47) | CACNA1BHDAC6 | |
| SCHEMBL4640082 | 0.71 | FGFR1 (0.47) | FDPSFGFR1FGFR4P2RX7HDAC6 | |
| SCHEMBL15496827 | 0.71 | HDAC6 (0.47) | HDAC6 | |
| SCHEMBL28110304 | 0.71 | HDAC6 (0.47) | HDAC6 | |
| SCHEMBL3570080 | 0.70 | CACNA1B (0.43) | CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217050-B2 | Adenine derivative as inhibitors of HSP90 for the treatment of cancer | CHROMA THERAPEUTICS LIMITED (GB) | 2012-07-10 | — | — | US | disclosed |
| US-20100035901-A1 | ADENINE DERIVATIVE AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. | 2010-02-11 | — | — | US | disclosed |
| EP-2084161-A1 | ADENINE DERIVATIVES AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER | Chroma Therapeutics Limited (GB) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008056120-A1 | ADENINE DERIVATIVES AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035901-A1 | ADENINE DERIVATIVE AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER | HSP90AA1, HSP90AB1, HSP90B1 | CACNA1B 4810/4885FDPS 3961/4885FGFR1 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.